Loyal for Dogs

Loyal for Dogs' Mission

Loyal for Dogs is dedicated to extending the healthspan and lifespan of dogs through the development of innovative drugs. As a subsidiary of Cellular Longevity, a San Francisco-based biotech firm, the company is at the forefront of veterinary biotechnology. Loyal for Dogs focuses on preventative care, addressing the underlying causes of age-associated diseases in dogs. Their mission is not only to lengthen the lives of dogs but also to ensure they remain healthy and active throughout their extended lifespan.

Loyal for Dogs' Funding and Financial Backing

Loyal for Dogs has successfully raised over $125 million in funding, reflecting significant investor confidence in their mission and technology. This substantial financial backing has enabled the company to invest heavily in research and development, driving forward their ambitious projects aimed at improving canine health and longevity. The funding supports extensive clinical trials and product development, ensuring that Loyal for Dogs remains at the cutting edge of veterinary medicine.

Loyal for Dogs' Products in Development

Loyal for Dogs is currently developing several promising products, including LOY-001, LOY-002, and LOY-003. LOY-002, which focuses on correcting metabolic dysfunction in senior dogs, is projected to be available in early 2025. LOY-001 and LOY-003 target large dogs, addressing the overexpression of IGF-1 and growth hormone, with a projected release in late 2026. These products aim to address the root causes of age-associated diseases, promoting longer and healthier lives for dogs.

Loyal for Dogs' Clinical Trials and FDA Support

Loyal for Dogs has launched a significant clinical study for LOY-002, enrolling 1,000 senior dogs across 55 veterinary clinics. This study is part of the first longevity clinical study design supported by the FDA, showcasing the company's pioneering approach in veterinary science. Additionally, the FDA has accepted a Reasonable Expectation of Effectiveness application for LOY-001, further validating the potential of Loyal for Dogs' innovative treatments.

Loyal for Dogs' Partnerships

Loyal for Dogs has partnered with Crinetics Pharmaceuticals for drug development, leveraging Crinetics’ expertise in endocrine therapies. This collaboration enhances Loyal for Dogs' capabilities in creating effective treatments for age-related conditions in dogs. The partnership is a strategic move to accelerate the development and commercialization of their innovative products, ensuring that they can bring life-extending treatments to market more efficiently.